Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15

Nina Möker; Solveig Peters; Robert Rauchenberger; Nicolae Ghinea; Christian Kunz; Antibodies Editorial Office

doi:10.3390/antib7030031

,

and

¹

MorphoSys AG, Discovery Alliance and Technologies, 82152 Planegg, Bavaria, Germany

²

Curie Institute, Inserm-Tumoral Angiogenesis Unit, Translational Research Department, Curie Hospital, 75005-Paris, France

³

MDPI, St. Alban-Anlage 66, 4052 Basel, Switzerland

^*

Author to whom correspondence should be addressed.

Antibodies2018, 7(3), 31;https://doi.org/10.3390/antib7030031

Version Notes

Order Reprints

The authors wish to make the following correction to the Conflict of Interests section in their published paper [1]:

“Christian Kunz and Solveig Peters are employees and Nina Möker and Robert Rauchenberger are former employees of MorphoSys AG, which owns the Ylanthia antibodies described in the publication.”

The manuscript will be updated and the original will remain online on the article webpage.

Reference

Moeker, N.; Peters, S.; Rauchenberger, R.; Ghinea, N.; Kunz, C. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15. [Google Scholar] [CrossRef]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Correction: Moeker, N.; et al. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15

Reference

Article Metrics

Citations

Article Access Statistics